HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (16)
  • Publications (14)
  • References (21)
  • Uncategorized (6)

Recent Posts

April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio
April 7, 2025

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

by PJWCreative
January 13, 2025

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

by PJWCreative
December 18, 2024

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

by PJWCreative
Post placeholder image
September 18, 2024

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 16, 2024

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
August 30, 2023 in References

Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment

PJWCreative 0 Like Post Comments Off on Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment
Read More
Post placeholder image
August 23, 2023 in References

Comparative properties and methods of preparation of lipid vesicles (liposomes)

PJWCreative 0 Like Post Comments Off on Comparative properties and methods of preparation of lipid vesicles (liposomes)

Click here

Read More
Post placeholder image
May 24, 2023 in References

Gluagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
April 3, 2023 in References

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
August 30, 2022 in References

Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
July 17, 2022 in References

Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

PJWCreative 0 Like Post Comments Off on Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer
Read More
Post placeholder image
August 31, 2021 in References

Surface Ligand Valency and Immunoliposome Binding: when More Is Not Always Better

PJWCreative 0 Like Post Comments Off on Surface Ligand Valency and Immunoliposome Binding: when More Is Not Always Better
Read More
Post placeholder image
September 30, 2020 in References

When liposomes met antibodies: Drug delivery and beyond

PJWCreative 0 Like Post Comments Off on When liposomes met antibodies: Drug delivery and beyond
Read More
Post placeholder image
June 24, 2020 in References

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
September 28, 2019 in References

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

PJWCreative 0 Like Post 0 Comment
Read More
Prev123Next

Download Company Profile

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin
HIGHfield_logo_horizontal_FINAL_trans

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

HIGHFIELD_web_LI_icon_x75

© 2024 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文